Carteolol

Carteolol

Systematic (IUPAC) name
(RS)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-3,4-dihydroquinolin-2(1H)-one
Clinical data
Trade names	Ocupress
AHFS/Drugs.com	Micromedex Detailed Consumer Information
MedlinePlus	a601078
Pregnancy cat.	C(US)
Legal status	℞ Prescription only
Routes	Eye drops
Pharmacokinetic data
Bioavailability	85%
Metabolism	Hepatic, active with 8-hydrocarteolol
Half-life	6–8 hours
Excretion	Renal (50-70%)
Identifiers
CAS number	51781-06-7
ATC code	C07AA15 S01ED05
PubChem	CID 2583
DrugBank	APRD00195
ChemSpider	2485 Y
UNII	8NF31401XG Y
KEGG	D07624 Y
ChEBI	CHEBI:3437 Y
ChEMBL	CHEMBL839 Y
Chemical data
Formula	C16H24N2O3
Mol. mass	292.373 g/mol
SMILES	eMolecules & PubChem
InChI InChI=1S/C16H24N2O3/c1-16(2,3)17-9-11(19)10-21-14-6-4-5-13-12(14)7-8-15(20)18-13/h4-6,11,17,19H,7-10H2,1-3H3,(H,18,20) Y Key:LWAFSWPYPHEXKX-UHFFFAOYSA-N Y
Y(what is this?)  (verify)

Carteolol (trade names Cartrol, Ocupress, Teoptic, Arteolol, Arteoptic, Calte, Cartéabak, Carteol, Cartéol, Cartrol, Elebloc, Endak, Glauteolol, Mikelan, Poenglaucol, Singlauc) is a non-selective beta blocker used to treat glaucoma.

External links

• El-Kamel A, Al-Dosari H, Al-Jenoobi F (2006). "Environmentally responsive ophthalmic gel formulation of carteolol hydrochloride.". Drug Deliv 13 (1): 55–9. doi:10.1080/10717540500309073. PMID 16401594. 
• Kuwahara K, Oizumi N, Fujisawa S, Tanito M, Ohira A (2005). "Carteolol hydrochloride protects human corneal epithelial cells from UVB-induced damage in vitro.". Cornea 24 (2): 213–20. doi:10.1097/01.ico.0000141232.41343.9d. PMID 15725891. 
• Trinquand C, Romanet J, Nordmann J, Allaire C (2003). "[Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study]". J Fr Ophtalmol 26 (2): 131–6. PMID 12660585.